ORGO Q4 2025 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$226M+78.1% YoY

Gross Profit

$164M72.8% margin

Operating Income

$75M33.2% margin

Net Income

$44M19.4% margin

EPS (Diluted)

$0.27

QoQ Revenue Growth

+49.5%

Cash Flow

Operating Cash Flow

$39M

Free Cash Flow

$35M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$599M

Total Liabilities

$165M

Stockholders' Equity

$434M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$226M	$127M	+78.1%
Gross Profit	$164M	$96M	+71.9%
Operating Income	$75M	$10M	+633.7%
Net Income	$44M	$8M	+469.5%

Revenue Segments

Product

$312M100%

Grant

$536,0000%